BioSpace News Archive

Aquinnah Pharmaceuticals announced today that it has signed an agreement with Roche to advance the development of brain penetrant oral small molecules to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Laurent Pharmaceuticals Inc. today announced that Luminis Health Research Institute in Annapolis MD, USA, has dosed the first patient in the Phase 3 expansion of the RESOLUTION Phase 2/3 clinical trial evaluating the efficacy of the novel COVID-19 oral antiviral LAU-7b.

National Resilience, Inc. today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.

NanoMosaic Inc., the pioneer and leader in nanoneedle (MosaicNeedle™) technology detection for proteomics, genomics, and single-run experiment multi-omics applications, has announced its second commercial sale, to Massachusetts General Hospital (MGH) as part of its Early Access Program.

BiondVax Pharmaceuticals Ltd. today announced that CEO Amir Reichman is presenting at the BIO CEO & Investor Conference being held this week.

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022.

Jaguar Health today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

The American Kidney Fund (AKF) today launched recently enhanced materials in its diversity in clinical trials patient education campaign to equip people of color, who are routinely underrepresented in clinical trials, with accessible information to increase understanding of, and participation in, clinical trials.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd.

Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), announced today the pricing of its underwritten public offering of 1,882,353 units at a price to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses.